公开(公告)号：US10167251B2

公开(公告)日：2019-01-01

申请号：US15374916

申请日：2016-12-09

Applicant: BioElectron Technology Corporation

Inventor： Orion D. Jankowski ,  Kieron E. Wesson ,  Paul Mollard ,  William D. Shrader

IPC: C07C235/80 ,  C07C235/78 ,  C07C317/28 ,  C07D207/27 ,  C07D211/46 ,  C07D213/40 ,  C07D233/61 ,  C07D295/13 ,  C07D295/192 ,  C07D265/30 ,  C07D311/66 ,  C07D207/26 ,  C07D213/50 ,  C07D295/116 ,  C07D295/185

Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, an well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

公开(公告)号：US10071978B2

公开(公告)日：2018-09-11

申请号：US15068452

申请日：2016-03-11

Applicant: BioElectron Technology Corporation

Inventor： Kieron W. Wesson ,  Andrew W. Hinman ,  Orion D. Jankowski

IPC: C07D311/72 ,  C07C46/02

Abstract: The invention discloses novel processes for production, enrichment and/or isolation of alpha-tocotrienol from source material comprising at least one non-alpha-tocotrienol, such as natural extracts comprising mixed tocotrienols.

公开(公告)号：US09932286B2

公开(公告)日：2018-04-03

申请号：US14983330

申请日：2015-12-29

Applicant: BioElectron Technology Corporation

Inventor： Guy M. Miller ,  Sidney M. Hecht ,  Orion D. Jankowski ,  Kieron E. Wesson ,  Paul Mollard

IPC: C07C50/38 ,  C07C50/04 ,  A61K31/05 ,  A61K31/355 ,  C07C39/08 ,  C07C39/11 ,  C07C39/19 ,  C07C39/24 ,  C07C50/02 ,  C07C50/06 ,  C07C50/24 ,  C07C50/28 ,  C07C215/56 ,  C07C403/04 ,  C07C403/08 ,  C07C403/18 ,  C07C43/225 ,  C07C43/23 ,  C07C47/277 ,  C07C69/608 ,  C07C69/618 ,  C07C233/27 ,  C07C233/32 ,  C07C255/37

CPC classification number: C07C50/04 ,  A61K31/05 ,  A61K31/355 ,  C07C39/08 ,  C07C39/11 ,  C07C39/19 ,  C07C39/245 ,  C07C43/225 ,  C07C43/23 ,  C07C47/277 ,  C07C50/02 ,  C07C50/06 ,  C07C50/24 ,  C07C50/28 ,  C07C69/608 ,  C07C69/618 ,  C07C215/56 ,  C07C233/27 ,  C07C233/32 ,  C07C255/37 ,  C07C403/04 ,  C07C403/08 ,  C07C403/18 ,  C07C2601/16

Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

公开(公告)号：US20190270699A1

公开(公告)日：2019-09-05

申请号：US16228657

申请日：2018-12-20

Applicant: BIOELECTRON TECHNOLOGY CORPORATION

Inventor： Orion D. Jankowski ,  Kieron E. Wesson ,  Paul Mollard ,  William D. Shrader

IPC: C07C235/80 ,  C07C235/78 ,  C07C317/28 ,  A61P25/16 ,  A61P27/00 ,  A61P25/00 ,  C07C235/32 ,  A61P21/00 ,  C07D207/27 ,  C07D295/185 ,  C07D295/116 ,  C07D213/50 ,  C07D207/26 ,  C07D311/66 ,  C07D265/30 ,  C07D295/192 ,  C07D295/13 ,  C07D233/61 ,  C07D213/40 ,  C07D211/46

Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinoly)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.